乳腺癌长期辅助性三苯氧胺治疗

对６３例激素受体阳性乳腺癌长期辅助性三苯氧胺治疗的疗效、安全性及预防乳腺第二原发癌的作用回顾性分析。可评仨者６１例。总的５年生存率、无瘤生存率分别为６５．６％和５４．５％。小于５０岁、５０岁及以上，绝经前、后，腋淋巴结阳性及阴性者５年生存率分别为５５．７％、７７．８％，５０．３％、７９．１％，６３．６％和８０．０％（各组Ｐ＜０．０５）。１例子宫内膜呈不典型性增生，１例发生对侧乳腺第二原发癌（１．６％）。表明长期辅助性三苯氧胺治疗能提高５年生存率，安全可靠，可预防乳腺第二原发癌，但应警惕子宫内膜癌发生。

Long-Term Adjuvant Tamoxifen Therapy in Postoperative Breast Cancer

We retrospectively evaluated curative effect,safety and prevention effect of second primary breast cancer in long-term adjuvant tamoxifen (TAM) therapy for 61 postoperative breast cancer patients with hormone receptor positive. The five-year survival rate (SR),disease free survival rate (DFSR) were 65 6% and 54 5%,respectively. The five-year SR of patients under 50 years old, 50 years and above, premenopausal, postmenopausal, axillary node positive and negative were 55 7% vs 77 8%,50 3% vs 79 1% and 63 6% vs 80 0% (P<0 05). The contralateral primary breast cancer occurred in one patient (1 6%). Atypical endometrial hyperplasia was pathologically diagnosed in one patient. Long-term adjuvant TAM therapy could increase the five-year SR and prevent the second primary breast cancer. There were less side effects. But we should be alert the dangerous of endometrial cancer.